{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:17:48Z","timestamp":1761743868005},"reference-count":19,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jpba.2013.12.007","type":"journal-article","created":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T08:48:08Z","timestamp":1387097288000},"page":"215-221","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Isolation, identification and characterization of degradant impurities in Tolterodine tartrate formulation"],"prefix":"10.1016","volume":"90","author":[{"given":"Lakkireddy","family":"Prakash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Himaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Venkata","family":"Subbaiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Vasudev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Srinivasulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Haribabu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2013.12.007_bib0020","series-title":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Q1A (R2), Stability Testing of New Drug Substances and Products","first-page":"1","year":"2003"},{"key":"10.1016\/j.jpba.2013.12.007_bib0025","series-title":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Q3A (R2), Impurities in New Drug substances","first-page":"1","year":"2006"},{"key":"10.1016\/j.jpba.2013.12.007_bib0030","series-title":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Q3B (R2), Impurities in New Drug Products","first-page":"1","year":"2006"},{"key":"10.1016\/j.jpba.2013.12.007_bib0035","series-title":"U.S. Food and Drug Administration Drug Stability Guidelines","year":"1987"},{"key":"10.1016\/j.jpba.2013.12.007_bib0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0165-9936(03)00701-5","article-title":"New safe medicines faster: the role of analytical chemistry","volume":"22","author":"G\u00f6r\u00f6g","year":"2003","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2013.12.007_bib0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/jps.2600670405","article-title":"Stability of pharmaceuticals","volume":"67","author":"Mollica","year":"1978","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2013.12.007_bib0050","series-title":"Handbook of Isolation and Characterization of Impurities in Pharmaceuticals","author":"Ahuja","year":"2003"},{"key":"10.1016\/j.jpba.2013.12.007_bib0055","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0731-7085(03)00017-7","article-title":"Development of a LC\u2013LC\u2013MS complete heart-cut approach for the characterization of a pharmaceutical compounds using standard instrumentation","volume":"31","author":"Sheldon","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2013.12.007_bib0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/157341208786306199","article-title":"Recent advances in the impurity profiling of drugs","volume":"4","author":"Bartos","year":"2008","journal-title":"Curr. Pharm. Anal."},{"key":"10.1016\/j.jpba.2013.12.007_bib0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0731-7085(03)00293-0","article-title":"An overview of the recent trends in development of HPLC methods for the determination of impurities in drugs","volume":"33","author":"Rao","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2013.12.007_bib0070","series-title":"Advanced Chromatographic and Electromigration Methods in Biosciences","first-page":"834","article-title":"Monitoring of process impurities in drugs","author":"Husain","year":"1998"},{"key":"10.1016\/j.jpba.2013.12.007_bib0075","series-title":"Analyses of Drug Impurities","author":"Smith","year":"2007"},{"key":"10.1016\/j.jpba.2013.12.007_bib0080","first-page":"3659","article-title":"Identification, isolation and quantification of unknown impurity in Tolterodine tartrate tablets by stability indicating HPLC method","volume":"4","author":"Reddy","year":"2012","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/j.jpba.2013.12.007_bib0085","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1365\/s10337-008-0735-y","article-title":"Development and validation of a new analytical method for the determination of related components in Tolterodine tartarate using LC","volume":"68","author":"Madhavi","year":"2008","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2013.12.007_bib0090","first-page":"144","article-title":"A validated stability indicating HPLC method for the determination of related substances and assay of Tolterodine tartrate","volume":"2","author":"Krishna","year":"2009","journal-title":"Rasayan J. Chem."},{"key":"10.1016\/j.jpba.2013.12.007_bib0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3797\/scipharm.1110-14","article-title":"A new rapid and sensitive stability indicating assay method for Tolterodine tartrate: application in pharmaceuticals, human plasma and urine sample","volume":"80","author":"Yanamandra","year":"2012","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.jpba.2013.12.007_bib0100","first-page":"242","article-title":"Stability-indicating HPLC determination of Tolterodine tartrate in pharmaceutical dosage form","volume":"13","author":"Saxena","year":"2006","journal-title":"Ind. J. Chem. Technol."},{"key":"10.1016\/j.jpba.2013.12.007_bib0105","first-page":"655","article-title":"Method development & validation of Tolterodine tartrate in bulk as well as in pharmaceutical formulation by using RP-HPLC","volume":"5","author":"Kumar","year":"2013","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jpba.2013.12.007_bib0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2007.12.021","article-title":"Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product","volume":"47","author":"Mohan","year":"2008","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851300592X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851300592X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T01:55:28Z","timestamp":1538963728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170851300592X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":19,"alternative-id":["S073170851300592X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2013.12.007","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolation, identification and characterization of degradant impurities in Tolterodine tartrate formulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2013.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}